Meropenem-resistant Burkholderia pseudomallei: a concerning single case in Australia with no prior meropenem exposure.

Access microbiology Pub Date : 2024-10-28 eCollection Date: 2024-01-01 DOI:10.1099/acmi.0.000619.v4
Pirathaban Sivabalan, Ferris Satyaputra, Ian Gassiep, Brian Forde, Jaimie Frazer, Matthew Glover, Buenafe Adams, Robert Norton
{"title":"Meropenem-resistant Burkholderia pseudomallei: a concerning single case in Australia with no prior meropenem exposure.","authors":"Pirathaban Sivabalan, Ferris Satyaputra, Ian Gassiep, Brian Forde, Jaimie Frazer, Matthew Glover, Buenafe Adams, Robert Norton","doi":"10.1099/acmi.0.000619.v4","DOIUrl":null,"url":null,"abstract":"<p><p>We report a case of cutaneous melioidosis in a 54-year-old male with a meropenem-resistant sub-population. He was empirically treated with episodic doxycycline and trimethoprim-sulfamethoxazole; however, the abscess re-accumulated. The patient had no prior exposure to meropenem. A sub-population of the isolate was meropenem resistant with an MIC >32 µg ml<sup>-1</sup> and the identification was re-confirmed as <i>Burkholderia pseudomallei</i>. Whole-genome sequencing with ARDaP analysis only revealed a resistance determinant to doxycycline and did not reveal a resistance determinant to meropenem. Furthermore, no carbapenemases were detected through multiple bioinformatics tools. To date, this is the first reported case in Australia of a <i>B. pseudomallei</i> isolate resistant to meropenem without previous carbapenem exposure.</p>","PeriodicalId":94366,"journal":{"name":"Access microbiology","volume":"6 10","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11652719/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Access microbiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1099/acmi.0.000619.v4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

We report a case of cutaneous melioidosis in a 54-year-old male with a meropenem-resistant sub-population. He was empirically treated with episodic doxycycline and trimethoprim-sulfamethoxazole; however, the abscess re-accumulated. The patient had no prior exposure to meropenem. A sub-population of the isolate was meropenem resistant with an MIC >32 µg ml-1 and the identification was re-confirmed as Burkholderia pseudomallei. Whole-genome sequencing with ARDaP analysis only revealed a resistance determinant to doxycycline and did not reveal a resistance determinant to meropenem. Furthermore, no carbapenemases were detected through multiple bioinformatics tools. To date, this is the first reported case in Australia of a B. pseudomallei isolate resistant to meropenem without previous carbapenem exposure.

美罗培南耐药假性伯克霍尔德菌:澳大利亚一例既往未接触美罗培南的病例。
我们报告一例皮肤类鼻疽在54岁男性与美罗培宁耐药亚人群。经验性治疗:间断性多西环素和甲氧苄氨苄磺胺甲恶唑;然而,脓肿再次积聚。患者之前没有接触过美罗培南。该分离菌亚群对美罗培南耐药,MIC值为32µg ml-1,再次鉴定为伪伯克霍尔德菌。全基因组测序和ARDaP分析仅显示对强力霉素的耐药决定因素,未显示对美罗培南的耐药决定因素。此外,通过多种生物信息学工具未检测到碳青霉烯酶。迄今为止,这是澳大利亚报告的第一例对美罗培南耐药的假芽孢杆菌分离株,此前没有碳青霉烯类接触。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.00
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信